Access & Resources
Getting started
on GIAPREZA
Ordering Info
CONTACT A DISTRIBUTOR
To order GIAPREZA, please contact one of the distributors below or download an Ordering Sheet.
If you would like more information about GIAPREZA or have questions related to research,
please contact a Medical Science Liaison.
Slide table to view more
| NDC Code | Distributors | Contact Information |
|---|---|---|
| NDC 68547-005-01 0.5 mg/mL vial option NDC 68547-501-02 2.5 mg/mL vial option | ASD Healthcare is now AmerisourceBergen specialty distribution | 1-800-746-6273 service@asdhealthcare.com |
| Cardinal Health Specialty Pharmaceutical Distribution | 1-866-677-4844 orderexpress.cardinalhealth.com | |
| McKesson Plasma and Biologics | 1-877-625-2566 mpb@McKesson.com | |
| Morris & Dickson Co., LLC | 1-800-388-3833 customerservice@morrisdickson.com |
Connect with a GIAPREZA sales
representative for information and support.
Important Safety Information
Indication
GIAPREZA® (angiotensin II) increases blood pressure in adults with septic or other distributive shock.
Contraindications
None.
Warnings and Precautions
The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in a randomized, double-blind, placebo-controlled study, ATHOS-3. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo-treated patients in the ATHOS-3 study (13% vs. 5%). The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism (VTE) prophylaxis.
Adverse Reactions
The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in ≥4% of patients treated with GIAPREZA and ≥1.5% more often than placebo‑treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.
Drug Interactions
Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.
You are encouraged to report negative side effects of prescription drugs to the FDA.
To report SUSPECTED ADVERSE REACTIONS, please contact:
Before administering, please see the Full Prescribing Information for GIAPREZA.